Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat

Transplantation

Volumn 66, Issue 12, 1998, Pages 1575-1580

  Vu, Minh Diem ^a   Qi, Shijie ^a   Xu, Dasheng ^a   Wu, Jiangping ^a   Peng, Junzheng ^a   Daloze, Pierre ^a   Sehgal, Suren ^b   Leduc, Bernard ^b   Chen, Huifang ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RAT;

ACUTE DISEASE; ANIMALS; DRUG SYNERGISM; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; RATS; RATS, INBRED BN; RATS, INBRED WF; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032573681     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00002     Document Type: Article

References (55)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
2. Borel JF. Cyclosporine: basic science summary. Transplant Proc 1988; 20 (suppl 2): 722.
3. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one year follow-up of a multicentre trial. Lancet 1983; 2: 986.
4. Canadian Multicentre Transplant Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809.
5. Bennett WM, Pulliam JP. Cyclosporine nephrotoxicity. Ann Intern Med 1983; 99: 851.
6. Ryffel B, Foxwell BM, Gee A, Greiner G, Woerly G, Mihatsch MJ. Cyclosporine - relationship of side effects to mode of action. Transplantation 1988; 46: 905.
7. Kumar MSA, White AG, Alex G, et al. Correlation of blood levels and tissue level of cyclosporine with the histologic features of cyclosporin toxicity. Transplant Proc 1988; 20: 407.
8. Tilney NL, Milford EL, Ajuro LL, et al. Experience with cyclosporine and steroids in clinical renal transplantation. Ann Surg 1984; 200: 605.
9. Kahan BD. Cyclosporine: a powerful addition to the immunosuppressive armametarium. Am J Kidney Dis 1984; 3: 444.
10. Sturrock ND, Lang CC, Struthers AD. Cyclosporin-induced nephrotoxicity and hypertension. Br J Hosp Med 1992; 48: 483.
11. Leaker B, Cairns HS. Clinical aspects of cyclosporin nephrotoxicity. Br J Hosp Med 1994; 52: 529.
12. Mason J. The effect of cyclosporin on renal function. J Autoimmun 1992; 5 (suppl A): 349.
13. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991; 23 (suppl 2): 19.
14. Platz KP, Bechstein WO, Eckhoff DE, Susuki Y, Sollinger HW. RS-61443 reverses acute rejection in dogs. Surgery 1991; 110: 736.
15. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
16. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy 1997; 17: 1178.
17. Hodge EE. The role of mycophenolate mofetil in clinical renal transplantation. World J Urol 1996; 14: 249.
18. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new anti-fungal antibiotic: I. Taxonomy of producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721.
19. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new anti-fungal antibiotic: II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727.
20. Baker H, Sidorowicz A, Sehgal SN, Vezina C. Rapamycin (AY-22, 989), a new anti-fungal antibiotic: III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978; 31: 539.
21. Calne RY, Collier DSJ, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
22. Morris RE, Meiser M. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 609.
23. Stepkowski SH, Chen H, Daloze P, Kahan B. Rapamycin, a new potent immunosuppressive drug for vascularized heart, kidney, and small bowel allografts. Transplantation 1991; 52: 22.
24. Chen HF, Wu JP, Luo HY, Daloze PM. The immunosuppressive effect of rapamycin on pancreaticoduodenal transplants in the rat. Transplant Proc 1991; 23: 2239.
25. Chen H, Wu J, Luo H, Daloze P. Reversal of ongoing rejection of allografts by rapamycin. Transplant Proc 1991; 23: 2241.
26. Chen H, Wu J, Xu D, Luo H, Daloze P. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993; 56: 651.
27. Luo H, Chen H, Daloze P, Chang J, Wu J. Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation 1992; 53: 1071.
28. Chen H, Luo H, Daloze P, et al. Long-term in vivo effects of rapamycin on humoral and cellular immune responses in the rat. Immunobiology 1993; 188: 303.
29. Chen H, Wu J, Xu D, Aboujaoude M, Daloze P. The effect of rapamycin on orthotopic small bowel transplantation in the rat. Transplant Proc 1992; 24: 1157.
30. Chen H, Luo H, Daloze P, Xu D, Wu J. Rapamycin-induced long-term allograft survival depends on persistence of alloantigen. J Immunol 1994; 152: 3107.
31. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 517: 225.
32. Lee S, Scott M, McMacedo AR. Pancreaticoduodenal transplantation in the rat: a technique update. Transplantation 1986; 42: 327.
33. Fisher B, Lee S. Microvascular surgical techniques in research: with special reference to renal transplantation in the rat. Surgery 1965; 58: 904.
34. Chou TC. The median-effect principle and combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout D, eds. Synergism and antagonism in chemotherapy. San Diego: Academic Press, 1991: 61.
35. Steptowski SM, Napoli KL, Wang ME, Qu X, Chou TC, Kahan BD. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporin on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996; 62: 986.
36. Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 1853.
37. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659.
38. Bechstein WO, Schilling M, Steele DM, Hullet DA, Sollinger HW. RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993; 25 (Pt 1): 702.
39. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991; 51: 27.
40. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolide. Transplant Rev 1992; 6: 39.
41. Collier DStJ, Calne RY, Pollard SG, Friend PJ, Thiru S. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23: 2246.
42. Almond PS, Moss A, Nakhleh RE, et al. Rapamycin: immunosuppression, hyporesponsiveness, and side effects in porcine renal allograft model. Transplantation 1993; 56: 275.
43. Ochiai T, Gunji Y, Nagata M, Akitoshi K, Asano T, Isono K. Effects of rapamycin in experimental organ allografting. Transplantation 1993; 56: 15.
44. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan BD. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55: 947.
45. Hartner WC, Van der Werf WJ, Lodge JPA, et al. Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine. Transplantation 1995; 60: 1347.
46. Vathsala A, Chou TC, Kahan BD. Analysis of interactions of immunosuppressive drugs with cyclosporine to inhibit DNA proliferation. Transplantation 1990; 49: 463.
47. Kahan BD. Immunosuppressive therapy. Curr Opin Immunol 1992; 4: 553.
48. Pirsch JD, Sollinger HW. Mycophenolate mofetil - clinical and experimental experience. Ther Drug Monit 1996; 18: 357.
49. Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17: 1148.
50. Sollinger HW, Beizer FO, Deierhoi MH, et al. RS-61443 (Mycophenolate Mofetil) - a multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513.
51. Laskow DA, Deierhoi MH, Hudson SH, Orr CL, Curtis JJ, Diethelm AG. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS-61443). Transplantation 1994; 57: 640.
52. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7: 161.
53. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161.
54. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33: 175.
55. Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 1994; 14: 1.